509 related articles for article (PubMed ID: 27236146)
21. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.
Solé C; Solà E; Huelin P; Carol M; Moreira R; Cereijo U; Mas JM; Graupera I; Pose E; Napoleone L; dePrada G; Juanola A; Fabrellas N; Torres F; Morales-Ruiz M; Farrés J; Jiménez W; Ginès P
Liver Int; 2019 Jul; 39(7):1246-1255. PubMed ID: 30597709
[TBL] [Abstract][Full Text] [Related]
22. Hepatorenal syndrome.
Angeli P; Morando F; Cavallin M; Piano S
Contrib Nephrol; 2011; 174():46-55. PubMed ID: 21921608
[TBL] [Abstract][Full Text] [Related]
23. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
Alessandria C; Venon WD; Marzano A; Barletti C; Fadda M; Rizzetto M
Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1363-8. PubMed ID: 12468959
[TBL] [Abstract][Full Text] [Related]
24. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
Goyal O; Sidhu SS; Sehgal N; Puri S
J Assoc Physicians India; 2016 Sep; 64(9):30-35. PubMed ID: 27762512
[TBL] [Abstract][Full Text] [Related]
25. [Hepatorenal syndrome in decompensated cirrhosis : A special form of acute renal failure].
Lenz K; Buder R; Lohr G; Piringer P; Voglmayr M
Med Klin Intensivmed Notfmed; 2016 Jun; 111(5):440-6. PubMed ID: 27241778
[TBL] [Abstract][Full Text] [Related]
26. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
[TBL] [Abstract][Full Text] [Related]
27. Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1.
Sendra C; Silva Ruiz MDP; Ferrer Rios MT; Alarcón García JC; Pascasio Acevedo JM
Gastroenterol Hepatol; 2018; 41(7):440-441. PubMed ID: 29054321
[No Abstract] [Full Text] [Related]
28. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
Caraceni P; Santi L; Mirici F; Montanari G; Bevilacqua V; Pinna AD; Bernardi M
Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
[TBL] [Abstract][Full Text] [Related]
29. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
Boyer TD; Sanyal AJ; Garcia-Tsao G; Regenstein F; Rossaro L; Appenrodt B; Gülberg V; Sigal S; Bexon AS; Teuber P;
Liver Transpl; 2011 Nov; 17(11):1328-32. PubMed ID: 21837734
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
31. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
[TBL] [Abstract][Full Text] [Related]
32. Renal Dysfunction in Cirrhotic Patients.
Carrion AF; Martin P
Am J Gastroenterol; 2019 Sep; 114(9):1407-1410. PubMed ID: 31397680
[No Abstract] [Full Text] [Related]
33. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
Narahara Y; Kanazawa H; Sakamoto C; Maruyama H; Yokosuka O; Mochida S; Uemura M; Fukui H; Sumino Y; Matsuzaki Y; Masaki N; Kokubu S; Okita K
J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
[TBL] [Abstract][Full Text] [Related]
35. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.
Sharma P; Moore K; Ganger D; Grewal P; Brown RS
Liver Transpl; 2020 Oct; 26(10):1328-1336. PubMed ID: 32574418
[TBL] [Abstract][Full Text] [Related]
36. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Gifford FJ; Morling JR; Fallowfield JA
Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
[TBL] [Abstract][Full Text] [Related]
37. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient.
Ibrisim D; Cakaloglu Y; Akyuz F; Karadag A; Ozdil S; Besisik F; Mungan Z; Okten A
Scand J Gastroenterol; 2006 Jul; 41(7):862-5. PubMed ID: 16785202
[TBL] [Abstract][Full Text] [Related]
38. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
Halimi C; Bonnard P; Bernard B; Mathurin P; Mofredj A; di Martino V; Demontis R; Henry-Biabaud E; Fievet P; Opolon P; Poynard T; Cadranel JF
Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
40. Hepatorenal syndrome.
Cárdenas A; Uriz J; Ginès P; Arroyo V
Liver Transpl; 2000 Jul; 6(4 Suppl 1):S63-71. PubMed ID: 10915194
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
